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Persistent infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) account for the majority of
cases of hepatic cirrhosis and hepatocellular carcinoma (HCC) worldwide. Small, non-coding RNAs play
important roles in virus-host interactions. We used high throughput sequencing to conduct an unbiased
profiling of small (14-40 nts) RNAs in liver from Japanese subjects with advanced hepatitis B or C and
hepatocellular carcinoma (HCC). Small RNAs derived from tRNAs, specifically 30–35 nucleotide-long 59
tRNA-halves (59 tRHs), were abundant in non-malignant liver and significantly increased in humans and
chimpanzees with chronic viral hepatitis. 59 tRH abundance exceeded microRNA abundance in most
infected non-cancerous tissues. In contrast, in matched cancer tissue, 59 tRH abundance was reduced, and
relative abundance of individual 59 tRHs was altered. In hepatitis B-associated HCC, 59 tRH abundance
correlated with expression of the tRNA-cleaving ribonuclease, angiogenin. These results demonstrate that
tRHs are the most abundant small RNAs in chronically infected liver and that their abundance is altered in
liver cancer.
H
epatitis B virus (HBV) and hepatitis C virus (HCV) are phylogenetically unrelated non-cytopathic viruses
that infect the liver1. While HBV is a DNA virus, and HCV is a positive-strand RNA virus, both have the
capacity to persist for years in some infected individuals. Hundreds of millions of people worldwide are
chronic carriers of HBV or HCV, 30–50% of whom have chronic liver disease2. Together, these viral infections are
responsible for ,60% of liver cirrhosis and ,80% of hepatocellular carcinoma (HCC), a leading cause of cancer-
related deaths worldwide. Numerous studies suggest that microRNAs (miRNAs), small 21–23 nt non-coding
RNAs are important in the pathogenesis of these infections, modulating viral replication as well as host responses
and possibly influencing the risk of carcinogenesis3. For example the HBV X protein represses expression of miR-
148a, potentially enhancing tumorigenesis4. In contrast, HCV infection is associated with higher expression of
miR-21, which targets key components of Toll-like receptor signaling pathways, possibly facilitating viral evasion
of innate immune responses5. miR-122 stabilizes HCV RNA and promotes its replication6,7, and the importance
of this interaction is reflected in the clinical development of an anti-miR-122 antagomir (miravirsen) as an
antiviral therapeutic8.
Somewhat larger, 30–35 nt RNAs derived from the 59 half of tRNA (59 tRHs) represent a second major class of
small non-coding RNA9. Increased expression of 59 tRHs has been associated with viral and rickettsial infections
in animals10,11, and may serve to prevent apoptosis and promote cell survival12. However, they have not been
studied previously in the context of viral hepatitis. To our knowledge, only one study has described unbiased
profiling of small RNAs in the liver during chronic viral hepatitis13, but the analysis was restricted to miRNAs. We
sequenced small (14–40 nts) RNAs in liver biopsies from subjects with chronic hepatitis and HCC, examining
both non-tumor and matched cancer tissue, and found a surprisingly high proportion of reads representing 59
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small RNAs in virus-infected liver, and show that their abundance is
altered in various disease states including hepatocellular carcinoma.
Results
tRNA-half abundance is significantly increased in chronic viral
hepatitis. We employed high-throughput sequencing to characterize
the small RNA transcriptome in liver tissue from Japanese adults
with advanced hepatitis B or hepatitis C and concomitant HCC (see
Supplemental Table 1 for patient information; see Supplemental
Tables 2–4 for summary statistics on RNA, qRT-PCR, and
sequencing). Initial studies focused on non-malignant tissue from
4 subjects with hepatitis B (mean age 53 6 4 yrs s.e.m.), 4 with
hepatitis C (63 6 2 yrs), and 4 uninfected individuals undergoing
resection of metastatic tumors (60 6 10 yrs)14. A large proportion of
the sequencing reads were 19–25 nts in length (median 38%, range
10–73%), as expected for miRNAs15 (Figure 1a, left). However, we
detected an equal or greater abundance of 30–35 nt reads in HBV-
and HCV-infected liver (median 54%, range 14–80%). These larger
RNAs were less abundant in uninfected tissue (median 21%, range
14–84%) and in human hepatoma (FT3-7) cells (median 9%, range
8.7–9.3%).
Most (,65%) of the 30–35 nt reads in infected samples aligned
perfectly to the region 59 of the anticodon triplet in annotated tRNA
genes16 (Figure 1b, Supplemental Figure 1, Supplemental Table 5 and
6). We refer to these as ‘‘59 tRNA-halves’’ (59 tRHs)9. Many of the
remaining 30–35 nt reads also aligned to the 59 end of tRNAs, par-
ticularly tRNAGly, but with one or more nucleotide deletions. Also
present were 39 tRHs (,36–39 nts) mapping to the region 39 of the
anticodon, including the 39 terminal CCA (Figure 1b, Supplemental
Figure 1). Additionally, we identified shorter reads derived from 39 or
59 tRNA termini, referred to previously as ‘‘tRNA fragments’’9 (tRFs),
or the region immediately 59 or 39 of the anticodon loop, but these
Figure 1 | tRH abundance in HBV- and HCV-infected liver. (a) (left) Read length distribution of 14–40 nt RNAs in non-malignant liver from
uninfected, HBV-, or HCV-infected subjects (n54 each), and FT3-7 cells (n53 replicates). (right) Proportion of reads mapping to miRNA versus tRNA
loci. Boxes represent median 6 1.5 * interquartile range. (b) tRNA coverage plot from the average of the 20 non-cancer samples. Dot size represents
percent of reads mapping at each base position within each tRNA (top 20 by average abundance). The anticodon is red, with 59 bases green and 39 bases
blue. Gray: bases of RNAs that are non-tRHs. See Supplemental Figure 1. (c) Proportion of mapped reads aligning to miR-122 versus the five most
abundant tRNA-derived RNAs. (d) (left) Expression levels (RT-qPCR) of miR-122, 59 tRHGly (‘‘Gly[C/G]CC’’) and 59 tRHVal (‘‘Val[A/C]AC’’) in
uninfected (n55–6), HBV-infected (n56–9) and HCV-infected (n514) human liver. Numbers of samples differ due to limited RNA. (right) Similar
results from uninfected (n55), HBV-infected (n59), and HCV-infected C (n55) chimpanzees. RNU48 was used as a normalizer. *P , 0.05; **P , 0.01;
***P , 0.005 by Mann-Whitney U-test. (e) ClustalW43 multiple sequence alignment of representative tRNAGly and tRNAVal genes from which 59 tRHGly
and 59 tRHVal could originate (see Supplemental Figure 3). tRNAs regions are highlighted according to the color scheme in panel (b). The box identifies a
unique conserved sequence motif described in the text. ‘‘Mapped reads’’ represents all reads aligning to miRNAs or tRNAs (see Methods).
www.nature.com/scientificreports
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were much less frequent. In 6 of 8 infected livers, more reads mapped
to tRNA loci16 than to known miRNAs17 (see Methods), while the
opposite was true in 3 of 4 uninfected tissues as well as FT3-7 cells
(Figure 1a, right).
There are 625 annotated tRNA genes in the human genome (hg19)
encoding 458 unique tRNA sequences. We identified reads mapping
to 348 of these 458 sequences. Notably, in 11 of the 12 subjects, the
same five 59 tRHs comprised .80% of tRNA-derived reads
(Supplemental Figure 2a). The two most abundant 59 tRHs were
Gly[C/G]CC (‘‘59 tRHGly’’), which could be derived from any of 10
tRNAGly genes with identical 59 sequence, and Val[A/C]AC (‘‘59
tRHVal’’), which could originate from any of 15 tRNAVal genes
(Figure 1b and C, Supplemental Figure 1 and 3, and Supplemental
Table 5)16. 59 tRHGly accounted for 54 6 9% (s.d.) and 59 tRHVal 17 6
9% of all tRNA-derived RNA reads (Supplemental Figure 2a).
Remarkably, 59 tRHGly abundance exceeded that of miR-122, one
of the most abundant liver miRNAs13, in 7 of 8 virus-infected tissues.
We used real-time reverse transcription quantitative PCR (RT-
qPCR) to validate these results and compare 59 tRHGly, 59 tRHVal
and miR-122 abundance in liver tissue from 22 additional subjects
(Supplemental Table 1–3)14. These analyses confirmed that 59 tRHGly
abundance was increased in HBV- and HCV-infected liver com-
pared with uninfected tissues (P,0.01 and P,0.05, respectively)
(Figure 1d, left). A similar trend was observed for 59 tRHVal (HBV
P50.07; HCV P50.7). 59 tRHGly and 59 tRHVal were more abundant
than miR-122 in HBV- and HCV-infected liver (59 tRHGly, P,0.005
for both HBV and HCV; 59 tRHVal, P,0.005 for HBV and P,0.01 for
HCV) (Figure 1d left). Notably, 59 tRHVal abundance was higher in
HBV- than in HCV-infected tissues (P,0.005).
Chimpanzees (Pan troglodytes) recapitulate many aspects of HBV
and HCV infections in humans18,19, and are free of potential con-
founding variables (e.g., alcohol intake, smoking) that are difficult to
control in human cohorts. Similar to humans, we found that intra-
hepatic 59 tRHGly and 59 tRHVal abundance was increased in archived
liver tissue from chimpanzees chronically infected with HBV com-
pared to uninfected animals (P,0.005 and P,0.05, respectively)
(Figure 1d, right, and Supplemental Table 7). However, 59 tRH
abundance was not increased in chronically HCV-infected chimpan-
zee liver.
In human tissues, the relative abundance of specific tRNA-derived
RNAs correlated with codon usage (codon frequency in DNA
sequence) (Spearman’s rho50.32, P50.01) and the number of pos-
sible tRNA genes from which each could originate (rho50.41,
P50.001) (Supplemental Figure 2b). However, tRNAs representing
potential sources of the five most abundant tRHs were not the most
highly ranked by gene number or codon usage, suggesting that addi-
tional factors likely determine tRH biogenesis (Supplemental Figure
4). Interestingly, those tRNAs from which 59 tRHGly and 59 tRHVal are
potentially derived share a unique sequence motif in the anticodon
stem-loop region (Figure 1e) not present in other tRNAs
(Supplemental Figure 3).
tRNA-half abundance is altered in viral hepatitis associated
cancer. In HCC tissue from HBV-infected subjects, RT-qPCR
analysis showed that 59 tRHGly and 59 tRHVal abundance was
significantly reduced (P,0.005 for both) (Figure 2a). Similar
reductions were evident in HCV-associated cancer tissue, but
significant only for 59 tRHVal (P,0.05). We then sequenced small
RNAs in cancer tissue from 4 HBV- and 4 HCV-infected subjects.
The proportion of reads mapping to tRNA genes was reduced in 4 of
7 samples for which a paired analysis with non-malignant liver was
possible, and relatively unchanged in the other 3 (Figure 2b).
Although tRNA-derived RNA expression profiles were similar
across non-malignant tissues from different subjects, there was
substantial variation when compared to cancer tissues (Figure 2c).
This suggests that the relative abundance of specific tRNA-derived
RNAs is altered in HCC. Notably, the relative abundance of 59 tRHGly
was reduced by ,50–60% in both HBV- and HCV-associated cancer
(Figure 2d).
tRNA-half abundance correlates with angiogenin levels in HBV-
associated cancer. Angiogenin (encoded by the gene ANG) is best
known for its role in angiogenesis, but several studies suggest its
RNase activity contributes to tRH biogenesis20,21. Consistent with
this, analysis of previous microarray data obtained from these
tissues14 revealed that ANG mRNA was reduced in both HBV- and
HCV-associated cancer compared to non-malignant tissue (P,0.01
and P,0.005, respectively) or uninfected liver (P,0.005 and
P50.01) (Figure 3a). Analysis of data from The Cancer Genome
Atlas (https://tcga-data.nci.nih.gov/tcga/) also indicates that ANG
expression is reduced in HCC compared to non-malignant tissue,
although the difference is significant only for HBV-associated cancer
(HBV P,0.005, HCV P50.12) (Supplemental Figure 5). ANG
mRNA abundance correlated strongly with 59 tRH expression in
the HBV-infected subjects we studied (59 tRHGly: Spearman’s
rho50.67, P,0.01; 59 tRHVal: rho50.74, P,0.005) (Figure 3b).
Quantitative immunoblot analyses (Supplemental Figure 6)
confirmed a correlation between ANG protein abundance and 59
tRH expression in HBV-associated cancer (59 tRHGly: rho50.83,
P,0.005; 59 tRHVal: rho50.87, P,0.005) (Figure 3c). ANG was
expressed within the cytoplasm of hepatocytes (Figure 3d), and
although its expression varied substantially in different tumors
(Figure 3e), reductions in ANG expression likely explain the
reduced tRH abundance we observed in most HBV-associated
cancers. Unfortunately, however, the available tissue sections from
these subjects were insufficient to power a formal analysis of the
correlation between cytoplasmic versus nuclear expression of ANG
and tRH abundance. ANG expression correlated poorly with tRH
abundance in HCV-infected livers, suggesting that other factors
determine tRH biogenesis.
Discussion
Recent advances in high-throughput sequencing technology have
unveiled the complexity and diversity of functional small RNAs.
We found that small RNAs derived from tRNAs, specifically 59
tRNA-halves9 (59 tRHs, ,30–35 nts), are abundant in liver, signifi-
cantly increased during chronic viral infection, and altered in abund-
ance in liver cancer associated with these infections. We do not
believe that these tRNA-halves are products of stochastic endonu-
clease cleavage of tRNAs for several reasons. First, the same tRNA-
halves were found to be increased in chronic viral hepatitis across all
individuals. Second, each tRNA-half family exhibited a uniform
length distribution (e.g., 59 tRHGly was represented primarily by reads
of length 32–34 in every individual). Third, tRNA-halves were pref-
erentially induced in chronic HBV infection (as compared to chronic
HCV infection) in both human and chimpanzee tissue, indicating
biological specificity. Finally, tRH abundance was correlated with
disease state (cancer versus non-cancer), indicating reproducible
sensitivity to the cellular environment.
Several models of disease have been shown to exhibit an increase
in tRH abundance, including cultured human airway cells infected
with respiratory syncytial virus22, mice infected with spotted-fever
group rickettsia23, and rats treated with cisplatin24. While their func-
tion is not well understood, previous work in cell culture suggests
that some tRHs promote cell survival, are anti-apoptotic12, reduce
translation25, and promote the formation of stress granules26.
Preliminary studies in our laboratory do not support a role for 59
tRHGly or 59 tRHVal in the regulation of global protein translation in
human hepatoma cells (Supplemental Figure 7–8); however, more
detailed investigation is required to uncover the potential functions
of tRHs. It has also been suggested that tRHs may alter the immune
response due to their enrichment in mouse lymphoid organs27, high
www.nature.com/scientificreports
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abundance in seminal exosomes (considered to be immunosuppres-
sive)28, and roles in facilitating Trypanosoma cruzi infection in
human cells and altering host gene expression29.
There is good evidence that the abundance of these small non-
coding RNAs increases in response to specific kinds of cellular stress.
For example, tRHs are induced in cell culture by the addition of sodium
arsenite, exposure to UV, nutrient starvation, hypoxia, hypothermia
and heat, but not by exposure to etoposide, c-radiation, caffeine30,31.
This strongly suggests that the formation of tRHs is a regulated process,
rather than due to general degradation of tRNAs in response to stress.
In the nucleus angiogenin is involved in promoting angiogenesis32 and
in the cytoplasm, when not bound to RNH1, it acts as a tRNA-proces-
sing RNase33,34, cleaving tRNAs at the anticodon loop and producing
tRHs30,31. The cellular localization of angiogenin and its ribonuclease
activity depend on the intracellular conditions and are regulated by
RNH133. The differences we observed in correlations between ANG
expression and tRH abundance in chronic hepatitis B, hepatitis C and
associated liver cancer may be a result of differences in angiogenin
localization and function in these disease states. Non-tumor and tumor
tissues from patients with chronic hepatitis C tend to show more
evidence of angiogenesis than the in chronic hepatitis B35,36. This could
mean that in chronic hepatitis C angiogenin is primarily nuclear, and
therefore not exclusively involved in tRH production. Finally, it must
also be noted that factors other than ANG may be critical to tRH
biogenesis in different cell types or in response to different types of
cellular stress. Much more remains to be uncovered about the specific
mechanisms that lead to tRH accumulation.
Chronic infections with HBV and HCV typically lead to more
severe liver disease in human patients than in the chimpanzee
model37,38. Disease severity may account for the differences we
observed in tRH abundance between liver tissue from human sub-
jects with chronic HCV infection and the chimpanzee samples.
Interestingly, however, humans and chimpanzees exhibited similar
increases in tRH abundance in chronic hepatitis B, suggesting that
Figure 2 | 59 tRH abundance in HBV- and HCV-associated hepatocellular carcinoma. (b) Abundance (RT-qPCR) of (left) 59 tRHGly (Gly[C/G]CC) and
(right) 59 tRHVal (Val[A/C]AC) in (top) non-malignant (n59) and cancer tissue (n510) from HBV-infected subjects, and (bottom) non-malignant
(n514), and cancer tissue (n515) from HCV-infected subjects. Box and whisker plots are overlaid with data from each sample; whiskers extend to 1.5 *
interquartile range. P-values calculated using Mann-Whitney U-test. *P , 0.05; **P , 0.01; ***P , 0.005. (b) Proportion of mapped reads aligning to
tRNAs for the paired cancer and non-cancer tissue from subjects with chronic hepatitis B (n53) and hepatitis C (n54) (c) Correlation heatmap of tRNA-
derived RNA expression profiles determined by small RNA sequencing. The colors of the cells represent Spearman’s rank correlation coefficients of the
relative levels of the 10 most abundant tRNA-derived RNAs between all pairs of tissue samples sequenced (n520). (d) Proportion of mapped reads that
align to 59 tRHGly and 59 tRHVal in non-malignant and cancer tissue from (top) HBV-infected and (bottom) HCV-infected subjects. ‘‘Mapped reads’’
represents all reads aligning to miRNAs or tRNAs (see Methods).
www.nature.com/scientificreports
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there may be a primary HBV-specific mechanism that directly reg-
ulates tRH biogenesis.
Our study has some technical limitations. tRNAs are subject to
many different chemical modifications39, several of which could
impede library preparation and sequencing. This may have biased
which tRNA-derived RNAs we detected. Also, we do not know how
tRH abundance varies among the diverse cell types that populate the
liver. Given that these small RNAs have not previously been studied
in human tissue, we also have little appreciation of what functions
these small non-coding RNAs have within the liver. Nonetheless, our
finding that the intrahepatic abundance of tRHs is substantially
increased in chronic viral infections of the liver and altered in
HCC suggest that tRHs may have important, yet to be determined
roles in liver disease. Thus, this study may have implications for
disease pathogenesis and novel therapeutic strategies.
Methods
The methods were carried out in accordance with the approved guidelines.
Human subjects. Written informed consent was obtained from all human subjects.
Ethics approval was obtained from the Ethics Committee for Human Genome/Gene
Analysis Research at Kanazawa University Graduate School of Medical Science.
Chimpanzee liver tissue. The chimpanzee samples used in this study were archived
from previous studies and were collected prior to December 15, 2011. Chimpanzees
were housed and cared for at the Southwest National Primate Research Center
(SNPRC) of the Texas Biomedical Research Institute. The animals were cared for in
accordance with the Guide for the Care and Use of Laboratory Animals, and all
protocols were approved by the Institutional Animal Care and Use Committee.
SNPRC is accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International. SNPRC operates in accordance
with the NIH and U.S. Department of Agriculture guidelines and the Animal Welfare
Act. Animals were sedated for all procedures. Animals are group-housed with indoor
and outdoor access and an environmental enrichment program is provided by a staff
of behavioral scientists.
Small RNA-sequencing. RNA was isolated as described previously14. RNA purity was
assessed with Nanodrop 2000 (Thermo Scientific) and integrity was determined with
an Agilent 2100 Bioanalyzer (Agilent). RNA integrity and sequencing quality were
comparable for all specimens (Supplemental Table 2–4). Small RNA libraries were
generated using Illumina TruSeq Small RNA Sample Preparation Kit (Illumina, San
Diego, CA). Sequencing was performed on Illumina HiSeq 2000 platform.
Bioinformatic analysis: Sequencing reads were trimmed using Cutadapt (parameters
O -10 e 0.1) and were further analyzed in two different ways: (i) Mapped trimmed
reads allowing no mismatches to all tRNA sequences (except pseudo-tRNAs and
undefined tRNAs) downloaded from GtRNAdb16 (Figure 1b,c; Figure 2c,d;
Supplemental Figure 1,2,4,7); (ii) Mapped trimmed reads to genomic regions
spanning annotated miRNA s40 (1/2 20 nts) and tRNA sequences (1/2 40 nts)
using Bowtie 0.12.741 allowing for no mismatches. Next, reads that did not map
Figure 3 | Angiogenin expression in viral hepatitis and hepatocellular carcinoma. (a) Normalized ANG mRNA levels from previously generated liver
microarray data14 from uninfected subjects (n56), non-malignant (n57) and liver cancer (n58) tissue from HBV-infected subjects, and non-malignant
(n511) and cancer tissue (n515) from HCV-infected subjects. **P , 0.01; ***P , 0.005, calculated by Mann-Whitney U-test. (b) Scatter plot of the
levels of 59 tRHs (RT-qPCR, -dCT normalized to RNU48) and ANG mRNA (microarray). 59 tRHGly (‘‘Gly[C/G]CC’’): uninfected subjects (n57), non-
cancer (n57) and cancer (n58) liver tissue from chronic hepatitis B subjects, and non-cancer (n511) and cancer (n515) liver tissue from chronic
hepatitis C subjects; 59 tRHVal: uninfected subjects (n56), non-cancer (n57) and cancer (n58) liver tissue from chronic hepatitis B subjects, and non-
cancer (n511) and cancer (n515) liver tissue of chronic hepatitis C subjects. (c) Scatter plot of the levels of 59 tRHs (RT-qPCR, -dCT normalized to
RNU48) and ANG protein expression (normalized to b-actin) determined by immunoblot analysis. (d) Immunohistochemistry staining for ANG in
formalin-fixed non-tumor (NT) and tumor tissue (T) from HBV-infected subject #10. (Right) Magnified view of non-tumor (NT). (e) ANG staining in
adjacent tumor nodules (T1 and T2) and in non-tumor (NT) tissue from HCV-infected subject #7.
www.nature.com/scientificreports
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without mismatches were aligned to the same regions using SHRiMP2.2.242.
SHRiMP2.2.2 seeds were set based on the length of the read allowing 1 mismatch
anywhere in the body and up to 3 mismatches at the 39 end of the read (based on the
length of the read). (Figure 1a right, Figure 2b, Supplemental Figure 7, Supplemental
Table 4). Small RNA-sequencing data was deposited on GEO (GSE57381).
AGO2-RNA Co-immunoprecipitation. FT3-7 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Life Technologies) and supplemented with 10%
fetal calf serum and 2 mM GlutaMAX (Life Technologies, Carlsbad, CA). Cells were
cultured in a humidified incubator at 37uC and 5% CO2. Three technical replicates of
1 3 107 FT3-7 cells were harvested in lysis buffer [150 mM KCl, 25 mM Tris-HCl
(pH 7.4), 5 mM EDTA, 1% Triton X-100, 5 mM DTT, Complete protease inhibitor
mixture (Roche), and 100 U/mL RNaseOUT (Life Technologies)]. Lysates were
centrifuged for 30 min at 17,000 3 g at 4uC and filtered through a 0.22-um filter.
Filtrates were incubated with anti-human AGO2 mAb (RN003M, MBL International,
Woborn, MA) or isotype control IgG (Abcam, Cambridge, England) at 4uC for 2 h,
followed by addition of 30 mL of Protein G Sepharose (GE Healthcare) for 1 h. The
Sepaharose beads were washed three times in lysis buffer and RNA extracted using the
miRNeasy Mini Kit (Qiagen, Hilden, Germany).
Small RNA real time quantitative PCR (RT-qPCR). Complementary DNA (cDNA)
was synthesized using TaqMan MicroRNA Reverse Transcription Kit (Life
Technologies) according to the manufacturer’s instructions. Real time PCR
amplification was performed using TaqMan Universal Master Mix (Life
Technologies) on the Bio-Rad CFX96 real time PCR detection system. U6, miR-24,
let-7a, let-7f, RNU48, and RNU66 were all evaluated as potential housekeeping small
RNAs for purposes of normalization. RNU48 was selected because it was the most
consistent across disease groups. RT-qPCR reactions for human samples were
performed in triplicate. RT-qPCR reactions for chimpanzee samples were performed
in duplicate. The following TaqMan assays were purchased from Life Technologies:
miR-122 (product number 4427975; 002245) and RNU48 or SNORD48 (product
number 4427975; 001006). Primers for the custom TaqMan assays (59 tRH-Gly and 59
tRH-Val) were designed using 59-GCAUUGGUGGUUCAGUGGUAGAAU-
UCUCGCCU-39 for 59 tRH-Gly and 59-GUUUCCGUAGUGUAGUGGUUAUCAC-
GUUCGCCU-39 for 59 tRHVal.
Metabolic Radiolabeling and Measurement of Nascent Protein Synthesis. Huh7
cells were seeded onto the wells of 6-well cell culture plates at a density of 2 3 105 cells/
well and incubated overnight to allow cell attachment. Cells were transfected with
50 nM and 100 nM of 59 tRHGly (59-GCAUUGGUGGUUCAGUGGUAGAAU-
UCUCGCCU-39), 59 tRHVal (59-GUUUCCGUAGUGUAGUGGUUAUCACGUU-
CGCCU-39), or scramble (59-GCAUUCACUUGGAUAGUAAAUCCAAGC-
UGAA-39)21 (all from Integrated DNA Technologies, Coralville, IA) oligonucleotide
after replacing cell culture medium with methionine- and cysteine-deficient DMEM
(Life Technologies) and cultured for further 12 hrs. Cells were then metabolically
radiolabeled for 12 hrs with 200 mCi/well of Express Protein Labeling Mix containing
[35S]methionine and [35S]cysteine (PerkinElmer, Waltham, MA) in the presence or
absence of 50 mg/ml puromycin and lysed with lysis buffer (20 mM Tris-HCl [pH
7.4] containing 150 mM NaCl, 1% Triton X-100, 0.05% SDS, and 10% glycerol)
supplemented with 50 mM NaF, 5 mM Na3VO4, and a protease inhibitor cocktail
(Complete; Roche, Mannheim, Germany). The protein concentration of cell lysates
was determined by the Bio-Rad Protein Assay (Bio-Rad), and 10 mg (total protein) of
cell lysates was subjected to SDS-PAGE followed by staining gels with the Sypro Ruby
Protein Gel Stain (Bio-Rad, Hercules, CA) and autoradiography.
Immunohistochemistry (IHC). Staining was performed by immunoperoxidase
technique with an Envision kit (DAKO Japan). Primary antibodies used were against
b-actin (Cell signaling technology, #4967, Beverly, MA) and Human Angiogenin
Affinity Purified Polyclonal Ab (R and D Systems, AF265, Minneapolis, MN).
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